Journal
PSYCHIATRY INVESTIGATION
Volume 8, Issue 2, Pages 161-168Publisher
KOREAN NEUROPSYCHIATRIC ASSOC
DOI: 10.4306/pi.2011.8.2.161
Keywords
Antidepressant; Bcl-xL; Fluoxetine; G alpha i2; Gs alpha; Microarray
Categories
Funding
- Hanyang University [HY-2010-N]
Ask authors/readers for more resources
Objective To analyze both differentially expressed genes and the Bcl-xL protein expression after acute and chronic treatment with fluoxetine in rat C6 glioma cells. Methods C6 glioma cells were cultured for 24 h or 72 h after treatment with 10 mu M fluoxetine, and gene expression patterns were observed using microarray and qRT-PCR. Then, cells were cultured for 6 h, 24 h, 72 h or 96 h after treatment with 10 mu M fluoxetine, and the expression of Bd-xL protein was measured using western blot. Results As determined by microarray, treatment with fluoxetine for 24 h up-regulated 33 genes (including Bcl-xL and NCAM140) and down-regulated 7 genes (including cyclin G-associated kinase). Treatment with fluoxetine for 72 h up-regulated 53 genes (including Gs alpha and Bcl-xL) and down-regulated 77 genes (including Gai2 and annexin V). Based on the qRT-PCR results, there was an increase in Gsa mRNA and a decrease in G alpha i2 mRNA at 72 h in fluoxetine-treated cells as compared to control, a result that was consistent with microarray. We also observed an increase in Bcl-xL mRNA (both at 24 h and at 72 h) in fluoxetine-treated cells as compared to control, demonstrating a tendency to increase gradually. Bcl-xL protein expression increased as the duration of fluoxetine treatment increased. Conclusion These results suggest that chronic treatment with fluoxetine not only initiates the cAMP pathway through inducing Gsa expression but also induces Bcl-xL expression, thus inhibiting apoptosis. Psychiatry Investig 2011;8:161-168
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available